Combination avelumab and axitinib has shown long-term activity in previously untreated patients with advanced renal cell carcinoma.
Some oncology practices are less likely than others to adopt immunotherapies within 2 years of regulatory approval, a study suggests.
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.
Combination ponatinib and blinatumomab produced durable responses in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in a phase 2 trial.
Talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses.
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
The prior authorization process can delay cancer care, leading to disease progression and death, according to a survey of ASCO members.
Axillary radiotherapy can replace axillary lymph node dissection in patients with sentinel node-positive early breast cancer, according to researchers.
The COVID-19 pandemic has hindered the early diagnosis and treatment of cancer, and this may have set back cancer outcomes by almost a decade in Europe, a new report suggests.
Bariatric surgery may reduce the risk of pancreatic cancer in patients with obesity who are younger than 50 years of age, a study suggests.
